Sat.Apr 23, 2022 - Fri.Apr 29, 2022

article thumbnail

Smartphone-based skin cancer diagnostic certified for use in UK

pharmaphorum

An artificial intelligence-powered digital tool for diagnosing skin cancers developed by Skin Analytics has been cleared in the UK as a Class IIA medical device, setting up broader use of the technology in patient assessments. DERM is being deployed in pilot studies across five NHS Trusts, for example to see if it can support GPs in referring patients to the urgent two week skin cancer referral laid out in NICE guidelines.

Hospitals 145
article thumbnail

Impel Pharmaceuticals upper-nasal delivery offers hope for migraine patients

Outsourcing Pharma

The companyĆ¢s Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How To Prepare A Successful PCD Pharma Business Plan?

Fossil Remedies

PCD Pharma Business Plan. In a pharmaceutical business, you need a link between the pharma marketing company and the end-user, i.e., doctors, pharmacists, or others who can prescribe the medicine. This connecting link is the PCD Pharma Business. The full form of PCD is Propaganda Cum Distribution. Are you a person who wants to know about the details of preparing a successful PCD pharma business plan?

article thumbnail

The Hard Part of Focus

The Honest Apothecary

Focus is the secret to improvement in any area of your life and career. What you focus on, you will get better at. Whether it be art, or sports, or business, or any other area of interest…focus makes the difference between progress and plateau. When an organization, or an individual, loses their focus, they will slowly but surely decline. No focus = no progress.

52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Digital interventions cut heart failure mortality, study shows

pharmaphorum

An analysis of 10 clinical trials of digital health interventions targeted at patients recently hospitalised for acute heart failure has found they improve outcomes compared to standard care. The meta-analysis by researchers in the US pooled the results of the studies to assess the impact of digital approaches like telemedicine, use of monitoring sensors, Internet-based interventions, smartphone apps, or text messaging/email interactions on all-cause mortality.

Hospitals 139
article thumbnail

Pharmacy FAQā€™s ā€“ About Me

The Luxe Pharmacist

Why did I go into pharmacy? I have a whole post post dedicated to this topic that I wrote years ago! You can read it HERE. But in short, I’ve always enjoyed STEM focused classes the most so I figured I would end up in some related field as an adult. The pharmacy specific spark first occurred through my own illness/medication side effects experience during high school and this experience is still something I carry with me everyday as a pharmacist as I now care for patients.

More Trending

article thumbnail

Connectivity, Sustainability and User Experience to transform packaging and drug delivery in next year: Pharmapack Europe 2022

Pharma Mirror

Paris, will open in May (18-19) with connectivity, sustainability and user experience identified as the key trends in 2022 influencing innovation across pharmaceutical packaging and drug delivery. The event ā€“ which unites major players in pharmaceutical packaging, drug delivery, medical devices and machinery ā€“ returns to the Paris Expo, Porte de Versailles (Hall 7.2) and will see 5000 attendees and some 300+ companies exploring next generation technologies and looking ahead to debate the major i

article thumbnail

Omnichannel Benchmarking: a new era of HCP engagement

pharmaphorum

As the landscape of healthcare changes, so too must the way that we interpret and measure performance and success. This is particularly evident in marketing. Before the COVID-19 pandemic, measuring engagement typically involved detailed follow-ups, contacting a pool of practitioners to gauge their awareness of a particular product and then extrapolating that information across the country.

Hospitals 116
article thumbnail

The FinTech Payment Story

Fuld

Robert H. Goddard, the father of modern rocket propulsion said, “It is difficult to say what is impossible, for the dream of yesterday is the hope of today and the reality of tomorrow.” Thanks to FinTech, from peer-to-peer lending to being rewarded for making our bill payments on time, the dream of a global cashless economy is more realistic than ever.

article thumbnail

Vocal biomarker use can elevate patient monitoring: Sonde Health

Outsourcing Pharma

A leader from the health tech company explains how voice-based technologies could transform monitoring of patients with dementia, AlzheimerĆ¢s, and other conditions.

52
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine

Pharma Mirror

OSAKA, Japan and TOKYO, Japan. Shionogi & Co., Ltd. and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary that specializes in artificial intelligence-driven biotechnology, is also participating in this research collaboration.

article thumbnail

Understanding the microbiome as an ā€˜overlooked critical organā€™

pharmaphorum

Compared to a ā€˜critical organā€™ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology. The interest in how the human microbiome influences health has grown substantially in the last decade.

article thumbnail

Assessing Medications in CKD ā€“ Case Study

Med Ed 101

KE is an 87-year-old female with a history of CKD. The most recent GFR was 21 mls/min which has remained stable from the most previous lab checks. Other diagnoses include atrial fibrillation, hypertension, GERD, back pain, muscle spasms, neuropathy, pruritus, and anxiety. She presents with her daughter today and she reports that she is most […].

45
article thumbnail

Yourway adds 100k square feet of temp-controlled storage capacity

Outsourcing Pharma

The addition of the facility in Pennsylvania will help meet the increasing demand for temperature-controlled clinical packaging, storage, and distribution.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care ā€“ all with our Pharmacy Cloud.

article thumbnail

Leading inhalation APIs expert Inke to triple production capacity

Pharma Mirror

Barcelona, Spain, April 20, 2022 ā€“ Inke, a leading global manufacturer of inhalation APIs wholly owned by Neuraxpharm Group, announces it is investing ā‚¬9 million to increase production capacity for inhalation APIs. The investment will allow Inke to triple the production capacity of chemical synthesis and the micronisation of inhalation APIs at its manufacturing plant in Castellbisbal, Barcelona, by 2024.

52
article thumbnail

AstraZeneca plans new US R&D hub as revenues rocket

pharmaphorum

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology drugs and heart failure therapy Farxiga. The new site will be at Kendall Square and will serve as the new corporate headquarters for Alexion ā€“ which is currently based across the Charles River in Boston’s Seaport District ā€“ as well as housing around 1,500 R&D staff from AZ and Alexion in a new purpo

Vaccines 111
article thumbnail

New long COVID study highlights key symptoms

Pharma Times

Women, those who are obese and those on mechanical ventilation are all more likely to suffer from the effects long-term COVID-19

61
article thumbnail

Thread buys CureClick to bring crowdsourced enrollment platform to DCTs

Outsourcing Pharma

The decentralized clinical trial specialist has acquired CureClick to add to its offerings a platform intended to expand awareness of study participation.

52
article thumbnail

NorthX Biologics signs GMP manufacturing collaboration agreement with Abera Bioscience

Pharma Mirror

Sweden-based NorthX Biologics (ā€œNorthXā€), which focuses on process development and large-scale production of advanced biological drugs, has signed a collaboration agreement with Abera Bioscience (ā€œAberaā€) for upscaling and GMP manufacturing of its vaccine candidate against pneumococcus, Ab-01.12. NorthX has recently established an innovation hub to offer support to partners in achieving their long-term drug development goals.

article thumbnail

Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1

pharmaphorum

Orders for Merck & Co’s oral antiviral for COVID-19 helped to swell the drugmaker’s first quarter revenues by a massive 50%, although underlying growth was also strong. Lagevrio (molnupiravir) added $3.2 billion to Merck’s top line of $15.9 billion, but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda (pembrolizumab) and the Gardasil human papillomavirus (HPV) vaccine range.

Vaccines 105
article thumbnail

NICE recommend exercise over painkillers for arthritis pain

Pharma Times

NICE urges older people to stop routine painkiller use – over 10 million in the UK suffer a form of arthritis or other joint conditions

48
article thumbnail

FDA approves Gilead's COVID-19 treatment for young children

Outsourcing Pharma

The US agency has expanded its approval of Veklury to include use in pediatric patients 28 days and older who have tested positive for the COVID-19 virus.

FDA 52
article thumbnail

Partnering to advance digital therapeutics offerings

pharmaphorum

Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . BehaVR and Sumitomo signed a potential $140 million deal to create virtual reality (VR) therapies to treat social anxiety disorder, generalised anxiety disorder, and major depressive disorder.

FDA 105
article thumbnail

Google, Sanofi back UK biotech OMassā€™ $100m second round

pharmaphorum

OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development. The Oxford-based company said the financing, led by venture capital arms of Google and Sanofi as well as Northpond Ventures, will be used to bring its portfolio of drug candidates for immunological and rare disease into clinical trials.

105
105
article thumbnail

Novo Nordisk once-weekly insulin clears first phase 3 test

pharmaphorum

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. The Danish drugmaker has reported the first phase 3 results with its new basal insulin product ā€“ insulin icodec ā€“ which backs up earlier data suggesting it could provide effective blood glucose control when injected just once a week.

98
article thumbnail

Pfizer/Biohaven migraine drug rimegepant gets EU green light

pharmaphorum

Pfizer’s $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug. The regulator cleared the oral CGRP inhibitor as Vydura for both treatment and prevention of episodic migraine attacks, becoming the first drug to be authorised for both uses in the EU, with a review also underway by the UK authorities.

FDA 98
article thumbnail

15 tips to (not) frustrate the heck out of your team

pharmaphorum

Oliver Stohlmannā€™s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post focuses on how poor managers frequently treat employees; it might hold some hints to support and retain strong talent ā€“ and benefit from their continued enthusiasm and drive for results.

article thumbnail

Biofourmis is digital healthā€™s latest unicorn, after raising $300m

pharmaphorum

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in fundraising in the first quarter. The Boston-based startup ā€“ which has a business model straddling digital therapeutics (DTx), artificial intelligence-powered patient management and provision of virtual care ā€“ said the Series D will be used to fund clinical trials of its DTx candidates, scale up its v

article thumbnail

Achieving diversity, equity and inclusion in clinical trials

pharmaphorum

Making sure clinical trials are diverse and representative of the populations theyā€™re studying isnā€™t just the right thing to do to promote inclusivity and equity; itā€™s also just good science/clinical scientific practice. But despite growing efforts to improve, many organisers still fall short when it comes to reaching, recruiting and retaining diverse patient populations in clinical trials.

FDA 98
article thumbnail

Cara, Vifor get EU okay for drug to treat itching in dialysis patients

pharmaphorum

Vifor Pharma and Cara Therapeutics’ Kapruvia has become the first drug to be approved in the EU to treat one of the most common and challenging side effects for people undergoing dialysis for chronic kidney disease (CKD) ā€“ chronic itching. The European Commission has cleared Kapruvia (difelikefalin) as an injectable treatment for chronic itching, also known as pruritus, in adult CKD patients on dialysis.

98
article thumbnail

Transparency, social change can help pharma regain the publicā€™s trust

pharmaphorum

Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in lockdown. Since then, inconsistent messaging around the need for booster shots, as well as side effects ā€“ no matter how rare ā€“ have tarnished their name.

article thumbnail

GSK beats forecasts, thanks to COVID antibody and Shingrix sales

pharmaphorum

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. Vir Biotechnology-partnered COVID-19 antibody Xevudy (sotrovimab) was the big contributor to the improved result, adding Ā£1.3 billion ($1.6 billion) to the company’s top-line of Ā£9.8 billion with no sales recorded in the prior year.

article thumbnail

Sanofi revs up manufacturing with help from McLaren

pharmaphorum

French drugmaker wants the efficiency of its manufacturing operations to go up a gear, and has joined forces with Formula One racing team McLaren to make it happen. The multi-year partnership will see McLaren work with Sanofi’s industrial affairs team, using its digital and analytics expertise to look at the pharma company’s manufacturing operations and find ways to improve efficiency.

97
article thumbnail

Readout sets up phase 3 for Valneva/Pfizerā€™s Lyme disease jab

pharmaphorum

There’s only one vaccine candidate for tick-borne infection Lyme disease in clinical development ā€“ Valneva and Pfizer’s VLA15 ā€“ and it has just moved another step closer to being available. The two partners have reported positive results in a phase 2 trial in paediatric patients aged five to 17, backing up earlier results in adults and setting up the start of a pivotal phase 3 trial in the third quarter of this year.